A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Purpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when administered as a 2-h infusion, but its use was limited by vascular toxicity. We investigated an alternative dosing strategy aimed at improving the safety profile of BAL101553....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Joerger, Markus, Stathis, Anastasios, Metaxas, Yannis, Hess, Dagmar, Mantiero, Mara, Mark, Michael, Volden, Matthias, Kaindl, Thomas, Engelhardt, Marc, Larger, Patrice, Lane, Heidi, Hafner, Peter, Levy, Nicole, Stuedeli, Silvia, Sessa, Cristiana, von Moos, Roger
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2019
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7340672/
https://ncbi.nlm.nih.gov/pubmed/31471863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00850-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars